Post ESMO / WCLC 2019

SCLC en Mesothelioom

Ben van den Borne, longarts

Catharina Ziekenhuis

2

Disclosures

3

Mesothelioom

4

5

6

7

8

Real-world data of nivolumab in

chemotherapy pre-treated

mesothelioma patients

D.W. Dumoulin MDL. Cantini MD, R.A. Belderbos MD, D. Mercieca MD,

R. Cornelissen MD, PhD, J.G.J.V. Aerts, MD, PhD

Erasmus MC

Rotterdam, the Netherlands

n mPFS (months, CI) mOS (months, CI) PR (%) DCR (%)

Nivo-Mes, Quispel, JTO 2018 34 2,6 (2,23-5,49) 11,8 (9,7-15,7) 24 47

MAPS2, Scherpereel, Lancet 2019 63 4,0 (2,8-5,7) 11,9 (6,7-17,7) 19 40

Erasmus MC 59 2,64 (1,56-4,20) 6,36 (4,92-9,12) 12 41

Results

Duration of response in patients with PR:

- Median: not reached

- Mean: 5.86+ months(2.76-10.8+)

Conclusion

In our real world data response rates and OS appears to be lower than in published results.

However, duration of response is clinically meaningful.

Identifying subgroup that is likely to respond is necessary.

DREAM <br /><br />A phase 2 trial of DuRvalumab with first line chEmotherApy in Mesothelioma with a safety run in

Presented By Anna Nowak at 2018 ASCO Annual Meeting

Slide 10

Presented By Anna Nowak at 2018 ASCO Annual Meeting

Progression free survival 6 months = 65% (n=31)

Presented By Anna Nowak at 2018 ASCO Annual Meeting

Slide 17

Presented By Anna Nowak at 2018 ASCO Annual Meeting

Maio, Lancet Oncol 2017; 18: 1261–73

DETERMINE: anti-CTLA4

CTLA4 en PD(L)-1 BlokkadeTremelimumab en durvalumab, fase II

Calabro, Lancet resp 2018

Nivolumab en ipilmumab, fase II (beide)

Disselhorst, Lancet resp 2019

Scherpereel, Lancet oncol 2019

Mediane PFS 6-7 maanden

Checkmate 743

Fase III, 600 patiënten !!

1e lijns chemotherapie vs nivolumab + ipilimumab

Studie een jaar vol, resultaten worden verwacht in 2020

19

Dendritic cell therapy

Tumor cell death and

release of antigen

Dendritic cell engulfs and

presents tumor antigen

T-cell activation

T-cell migration to tumor site

Chen et al. 2013

Cornwall et al. 2016

Proof of concept

Cornelissen, AACR 2019

Dendritic cell therapy: OS of Phase 1 trial

Aerts, CCR 2018

23

NVALT 19

Burgers, ESMO 2019

NVALT 19

Burgers, ESMO 2019

26

SCLC

Systemic therapy advances in SCLC 1985-2019

Ready, JTO 2019

Slide 32

Presented By Christine Hann at 2019 ASCO Annual Meeting

Checkmate 331; Nivolumab vstopotecan

Reck, ESMO IO 2018

Checkmate 331

Reck, ESMO IO 2018

Maintenance

Owonikoko, ELCC 2019

Checkmate 451

Owonikoko, ELCC 2019

Horn, N Engl J Med 2018 IMpower 133

Horn, N Engl J Med 2018 IMpower 133

Paz-Arez, WCLC 2019

Durvalumab plus platinum-etoposide in first-line ED SCLC:

the CASPIAN study

Paz-Arez, WCLC 2019

Durvalumab plus platinum-etoposide in first-line ED SCLC:

the CASPIAN study

IO in LD: Achilles trial

Lurbinectedin

Paz Ares L. ASCO 2019

OS Lurbinectedin

Paz Ares L. ASCO 2019

VRAGEN?